PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
Background. Breast cancer is the most common malignant tumor and accounts for the most number of cancer-related deaths among Russian women. Combination of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor ribociclib and aromatase inhibitor is approved for the first-line treatment of postmenopausal...
Enregistré dans:
Auteurs principaux: | , , , , |
---|---|
Format: | Livre |
Publié: |
ABV-press,
2018-08-01T00:00:00Z.
|
Sujets: | |
Accès en ligne: | Connect to this object online. |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Internet
Connect to this object online.3rd Floor Main Library
Cote: |
A1234.567 |
---|---|
Exemplaire 1 | Disponible |